Source: Annual Congress 2009 - Pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Levy, F. Bajolle, S. Cohen, D. Bonnet (Paris, France). Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension. Eur Respir J 2009; 34: Suppl. 53, 1488

Member's Comments

No comment yet.

Related content which might interest you: Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006 Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management Year: 2017 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science Source: Eur Respir J 2016; 47:1615-1617 Year: 2016 Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Successful artocoronary bypass grafting in a patient with severe idiopathic pulmonary arterial hypertension: use of intravenous treprostinil Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006 Experience with inhaled iloprost in paediatric pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach Source: Eur Respir J 2015; 45: 1142-1149 Year: 2015 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study Source: Eur Respir J 2012; 39: 772-775 Year: 2012 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011